NCT03719430 - APX005M and Doxorubicin in Advanced Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Soft Tissue Sarcoma

Interventions

DRUG

Doxorubicin

Doxorubicin is an anthracycline antibiotic with antineoplastic activity 75 mg/m2 IV day 1 (21 day cycles)

DRUG

APX005M

APX005M is a CD40 agonistic monoclonal antibody 0.3 mg/kg IV day 1 (21 day cycles)

Trial Locations (3)

Columbia University Irving Medical Center/NYP, New York

Washington University School of Medicine - Siteman Cancer Center, St Louis

City of Hope, Duarte

All Listed Sponsors

collaborator

Apexigen America, Inc.

INDUSTRY

lead

Alexander Z. Wei, MD

OTHER